Brokerages Set Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Price Target at $35.86

Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) have received a consensus recommendation of “Buy” from the nine research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $35.86.

Several equities research analysts have recently commented on DAWN shares. Needham & Company LLC reiterated a “buy” rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. Bank of America lowered their price objective on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research note on Monday, November 4th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a report on Thursday, October 31st.

Day One Biopharmaceuticals Stock Down 2.4 %

Shares of DAWN opened at $12.24 on Friday. The company has a market cap of $1.23 billion, a price-to-earnings ratio of -11.88 and a beta of -1.46. Day One Biopharmaceuticals has a twelve month low of $11.13 and a twelve month high of $18.07. The company has a 50 day moving average of $12.94 and a two-hundred day moving average of $13.89.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $0.38 EPS for the quarter, topping the consensus estimate of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analyst estimates of $15.05 million. During the same quarter in the previous year, the firm posted ($0.54) earnings per share. On average, sell-side analysts expect that Day One Biopharmaceuticals will post -0.85 EPS for the current year.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of Day One Biopharmaceuticals stock in a transaction on Monday, November 11th. The shares were sold at an average price of $16.10, for a total value of $161,000.00. Following the completion of the transaction, the insider now owns 1,057,535 shares of the company’s stock, valued at approximately $17,026,313.50. The trade was a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last quarter, insiders sold 51,745 shares of company stock valued at $748,567. Corporate insiders own 8.40% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. increased its holdings in Day One Biopharmaceuticals by 38.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock valued at $51,000 after buying an additional 1,002 shares in the last quarter. SteelPeak Wealth LLC increased its stake in shares of Day One Biopharmaceuticals by 9.8% during the third quarter. SteelPeak Wealth LLC now owns 17,400 shares of the company’s stock worth $242,000 after purchasing an additional 1,550 shares in the last quarter. Handelsbanken Fonder AB increased its stake in shares of Day One Biopharmaceuticals by 16.9% during the third quarter. Handelsbanken Fonder AB now owns 27,000 shares of the company’s stock worth $376,000 after purchasing an additional 3,900 shares in the last quarter. Martingale Asset Management L P increased its stake in shares of Day One Biopharmaceuticals by 9.6% during the third quarter. Martingale Asset Management L P now owns 71,304 shares of the company’s stock worth $993,000 after purchasing an additional 6,219 shares in the last quarter. Finally, Verition Fund Management LLC increased its stake in shares of Day One Biopharmaceuticals by 31.4% during the third quarter. Verition Fund Management LLC now owns 31,075 shares of the company’s stock worth $433,000 after purchasing an additional 7,422 shares in the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.